Current status of Guillain-Barré syndrome (GBS) in China : a 10-year comprehensive overview
© 2023 Walter de Gruyter GmbH, Berlin/Boston..
Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy; a disease involving the peripheral nervous system which is the most common cause of acute flaccid paralysis worldwide. So far, it is still lack of a comprehensive overview and understanding of the national epidemiological, clinical characteristics, and the risk factors of GBS in China, as well as differences between China and other countries and regions in these respects. With the global outbreak of the coronavirus disease 2019 (COVID-19), an epidemiological or phenotypic association between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and GBS has attracted great attention. In this review, we outlined the current clinical data of GBS in China by retrieving literature, extracting and synthesizing the data of GBS in China from 2010 to 2021. Besides, we compared the characteristics of epidemiology, preceding events and clinical profiles of GBS between China and other countries and regions. Furthermore, in addition to conventional intravenous immunoglobulin (IVIG) and plasma exchange (PE) therapy, the potential therapeutic effects with novel medications in GBS, such as complement inhibitors, etc., have become the research focus in treatments. We found that epidemiological and clinical findings of GBS in China are approximately consistent with those in the International GBS Outcome Study (IGOS) cohort. We provided an overall picture of the present clinical status of GBS in China and summarized the global research progress of GBS, aiming to further understand the characteristics of GBS and improve the future work of GBS worldwide, especially in countries with the middle and low incomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Reviews in the neurosciences - 34(2023), 8 vom: 15. Dez., Seite 869-897 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Song, Yanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chinese |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 08.12.2023 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/revneuro-2023-0024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356490904 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356490904 | ||
| 003 | DE-627 | ||
| 005 | 20231227131237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/revneuro-2023-0024 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM356490904 | ||
| 035 | |a (NLM)37145885 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Song, Yanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current status of Guillain-Barré syndrome (GBS) in China |b a 10-year comprehensive overview |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 08.12.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Walter de Gruyter GmbH, Berlin/Boston. | ||
| 520 | |a Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy; a disease involving the peripheral nervous system which is the most common cause of acute flaccid paralysis worldwide. So far, it is still lack of a comprehensive overview and understanding of the national epidemiological, clinical characteristics, and the risk factors of GBS in China, as well as differences between China and other countries and regions in these respects. With the global outbreak of the coronavirus disease 2019 (COVID-19), an epidemiological or phenotypic association between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and GBS has attracted great attention. In this review, we outlined the current clinical data of GBS in China by retrieving literature, extracting and synthesizing the data of GBS in China from 2010 to 2021. Besides, we compared the characteristics of epidemiology, preceding events and clinical profiles of GBS between China and other countries and regions. Furthermore, in addition to conventional intravenous immunoglobulin (IVIG) and plasma exchange (PE) therapy, the potential therapeutic effects with novel medications in GBS, such as complement inhibitors, etc., have become the research focus in treatments. We found that epidemiological and clinical findings of GBS in China are approximately consistent with those in the International GBS Outcome Study (IGOS) cohort. We provided an overall picture of the present clinical status of GBS in China and summarized the global research progress of GBS, aiming to further understand the characteristics of GBS and improve the future work of GBS worldwide, especially in countries with the middle and low incomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Chinese | |
| 650 | 4 | |a Guillain-Barré syndrome | |
| 650 | 4 | |a clinical features | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a prognosis | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a Zheng, Xiaoxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Kangding |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xiujuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews in the neurosciences |d 1987 |g 34(2023), 8 vom: 15. Dez., Seite 869-897 |w (DE-627)NLM074824201 |x 2191-0200 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:8 |g day:15 |g month:12 |g pages:869-897 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/revneuro-2023-0024 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 8 |b 15 |c 12 |h 869-897 | ||